|
|
|
Introducing Shilpa Gupta as the new editor of the Advanced Bladder Cancer Center of Excellence:
We are thrilled to welcome Shilpa Gupta, MD, as the new editor of UroToday's Advanced Bladder Cancer Center of Excellence. Dr. Gupta brings a wealth of expertise in genitourinary oncology and is committed to advancing the field with the latest diagnostic and treatment innovations for bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
The Best of ASCO 2024 in Advanced Bladder Cancer
|
|
Shilpa Gupta, MD
|
| Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial; and circulating tumor DNA assessment in the KEYNOTE-361 trial.
|
|
|
|
|
|
|
|
|
|
|
|
|
Novel Bladder Cancer Treatment: Mechanisms, Clinical Findings, and Implications
|
Patrick Soon-Shiong, MD
Ashish Kamat and Patrick Soon-Shiong explore the clinical development and FDA approval of Anktiva for bladder cancer. Dr. Soon-Shiong outlines the journey from initial studies in BCG-naive and BCG-unresponsive patients to approval. |
|
|
|
|
|
|
|
|
|
|
| Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians |
| Cora Sternberg, MD |
| Cora Sternberg discusses the significant advancement in the treatment of urothelial carcinoma, focusing on enfortumab vedotin (EV) in combination with pembrolizumab. This combination, recently approved in the US as a first-line therapy, has shifted the treatment paradigm, offering a potent alternative to traditional platinum-based therapies. |
|
|
|
|
|
|
|
|
|
|
|
|
Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings
|
Andrea Apolo, MD
Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with pembrolizumab versus observation. However, overall survival data is still maturing.
|
|
|
|
|
|
|
|
|
|
|
| Emerging Frontiers in Advanced Bladder Cancer: Paradigm Shifts in Diagnosis and Treatment |
| Shilpa Gupta, MD |
| Recent advancements in the diagnosis and treatment of advanced bladder cancer (aUC) have led to a paradigm shift. Immunotherapies, targeted therapies, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab have shown significant improvements in progression-free and overall survival compared to traditional platinum-based chemotherapy. These novel therapies are now recommended as the new standard of care, offering extended survival and improved quality of life for patients with aUC. |
|
|
|
|
|
| Characterization of Complete Responders to Nivolumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone and Patients with Lymph Node–Only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial
|
| Matt D. Galsky, MD, FASCO
|
| Matt Galsky presents a post hoc analysis from the CheckMate 901 trial, comparing complete responders to nivolumab combined with gemcitabine-cisplatin (GC) versus GC alone in patients with lymph node-only metastatic urothelial carcinoma. The analysis revealed that the combination therapy significantly improved overall survival, progression-free survival, and overall response rates, particularly in patients with lymph node-only mUC, compared to GC alone.
|
|
|
|
|
|
| PROs from a Randomized, Phase 3 Trial of Enfortumab Vedotin plus Pembrolizumab Versus Platinum-Based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
|
| Shilpa Gupta, MD
|
| Shilpa Gupta presents patient-reported outcomes from the EV-302 trial, comparing enfortumab vedotin plus pembrolizumab to platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial cancer. The combination therapy significantly improved progression-free and overall survival without detriment to quality of life and functioning.
|
|
|
|
|
|
|
|
|
|
|
| Quantitative Circulating Tumor DNA (ctDNA) Assessment in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab or Platinum-Based Chemotherapy from the Phase 3 KEYNOTE-361 Trial
|
| Thomas Powles, MBBS, MRCP, MD
|
| Thomas Powles presents an ad hoc analysis of ctDNA from the phase 3 KEYNOTE-361 trial, comparing pembrolizumab to platinum-based chemotherapy in advanced urothelial carcinoma. The analysis showed that lower baseline ctDNA levels were associated with better clinical outcomes in the pembrolizumab arm, but not in the chemotherapy arm. Patients treated with pembrolizumab had superior overall survival if they had low baseline ctDNA levels and meaningful ctDNA reductions.
|
|
|
|
|
|
| TAR-200 in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer: Results from the SunRISe-1 Study
|
| Joseph Jacob, MD, MCR
|
| Joseph Jacob presents the SunRISe-1 study results on TAR-200 for BCG-unresponsive high-risk non-muscle invasive bladder cancer. TAR-200, delivering gemcitabine locally, showed an 82.8% complete response rate by central review and 86.2% by investigator assessment, with rapid and durable responses—75.7% and 61.9% complete response rates at 6 and 12 months, respectively.
|
|
|
|
|
|
| Updated Results from AVENANCE: Real-World Effectiveness of Avelumab First-Line Maintenance in Patients with Advanced Urothelial Carcinoma and Analysis of Subsequent Treatments
|
| Philippe Barthelemy, MD, Ph.D.
|
| Philippe Barthelemy presented updated results from AVENANCE, a real-world study on the effectiveness of avelumab first-line maintenance in advanced urothelial carcinoma patients, alongside analysis of subsequent treatments. The study confirmed the long-term effectiveness and safety of avelumab, showing a median overall survival (OS) of 21.3 months from the start of avelumab treatment, with 1- and 2-year OS rates of 67% and 46%, respectively.
|
|
|
|
|
|
| N-803 Plus BCG Complete Response Rate in NMIBC CIS: BCG Refractory, Relapsed, Checkpoint Failure, and Chemotherapy Failure; Updated Results (QUILT 3.032)
|
| Patrick Soon-Shiong, MD
|
| Patrick Soon-Shiong presents updated results from the QUILT 3.032 trial, evaluating N-803 plus BCG in patients with BCG-unresponsive high-grade NMIBC. The trial reported a 65% overall complete response rate, with responses consistent across subgroups and durable, showing a median duration of 26.6 months. This combination therapy, involving the IL-15 superagonist N-803, demonstrated significant efficacy and a favorable safety profile for patients who had exhausted other treatment options, including chemotherapy and checkpoint inhibitors.
|
|
|
|
|
|
| Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
| Mark Tyson II, MD, MPH
|
| Mark Tyson presents results from the BOND-003 phase 3 trial, which evaluated intravesical cretostimogene grenadenorepvec for high-risk, BCG-unresponsive NMIBC. The trial showed a 75.2% complete response rate at any time and demonstrated durable responses, with 92.4% cystectomy-free survival and 96.7% progression-free survival at 12 months. Cretostimogene was generally well tolerated, with most adverse events being grade 1-2, and the FDA granted it fast track designation for BCG-unresponsive CIS.
|
|
|
|
|
|
|
|
|
|
|
